Q3 2015 13F Holders as of 30 Sep 2015
-
Type / Class
-
Debt / NOTE 0.750% 8/1
-
Unit price / market price
-
$1.30
-
Total 13F principal
-
$241,761,170
-
Principal change
-
+$217,316,170
-
Total reported value
-
$314,220,141
-
Number of holders
-
25
-
Value change
-
+$282,556,141
-
Number of buys
-
24
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q3 2015
As of 30 Sep 2015 LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 had 25 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $241,761,170 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included Linden Advisors LP, CAMDEN ASSET MANAGEMENT L P /CA, WOLVERINE ASSET MANAGEMENT LLC, CITADEL ADVISORS LLC, Allianz Asset Management AG, LAZARD ASSET MANAGEMENT LLC, DEUTSCHE BANK AG\, HIGHBRIDGE CAPITAL MANAGEMENT LLC, PALISADE CAPITAL MANAGEMENT LLC/NJ, and BASSO CAPITAL MANAGEMENT, L.P..
This table shows 25 bond principal holders of the security as of 30 Sep 2015.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.